Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593796 | 0.74 | PTGS1 (0.31) | PTGS1KCNH2 | |
| SCHEMBL22236866 | 0.65 | PTGS1 (0.50) | PTGS1KCNH2 | |
| SCHEMBL18339356 | 0.65 | PTGS1 (0.40) | PTGS1KCNH2 | |
| SCHEMBL3316071 | 0.65 | PTGS1 (0.36) | PTGS1KCNH2 | |
| SCHEMBL3316077 | 0.65 | PTGS1 (0.36) | PTGS1KCNH2 | |
| SCHEMBL10076382 | 0.60 | PTGS1 (0.47) | PTGS1KCNH2 | |
| SCHEMBL5329840 | 0.60 | PTGS1 (0.47) | PTGS1KCNH2 | |
| Ethylenediamine SCHEMBL28334089 | 0.60 | PTGS1 (0.43) | PTGS1KCNH2 | |
| SCHEMBL17664728 | 0.60 | PTGS1 (0.40) | PTGS1KCNH2 | |
| Pantoic Acid SCHEMBL213982 | 0.58 | PTGS1 (0.48) | PTGS1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092775-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3925959-A1 | FLUORINATED DERIVATIVES OF 3-(2-OXO-3-(3-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)PROPYL)IMIDAZOLIDIN-1-YL)PROPANOIC ACID AND USES THEREOF | OcuTerra Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210346400-A1 | TREATMENT OF FIBROSIS USING FXR LIGANDS | INTERCEPT PHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210277000-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2021-09-09 | — | — | US | disclosed |
| EP-3259271-B1 | FLUORINATED DERIVATIVES OF 3-(2-OXO-3-(3-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)PROPYL)IMIDAZOLIDIN-1-YL)PROPANOIC ACID AND USES THEREOF | SCIFLUOR LIFE SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10987362-B2 | Treatment of fibrosis using FXR ligands | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200397803-A9 | TREATMENT OF FIBROSIS USING FXR LIGANDS | INTERCEPT PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| EP-2712617-B2 | Treatment of fibrosis using Fxr ligands | INTERCEPT PHARMACEUTICALS INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3175855-B1 | TREATMENT OF FIBROSIS USING FXR LIGANDS | INTERCEPT PHARMACEUTICALS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20070292501-A1 | CHEWABLE SOFT GELATIN CAPSULES | SOFT GEL TECHNOLOGIES, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2006132879-A2 | SOFT GEL CAPSULES CONTAINING POLYMETHOXYLATED FLAVONES AND PALM OIL TOCOTRIENOLS | SOFT GEL TECHNOLOGIES, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060069070-A1 | Treatment of fibrosis using FXR ligands | INTERCEPT PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| US-20060003947-A1 | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols | THE CIT GROUP/CREDIT FINANCE, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050101565-A1 | Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders | ESPERION THERAPEUTICS, INC. | 2005-05-12 | — | — | US | disclosed |
| EP-1519751-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | Esperion Therapeutics Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-0323855-B1 | Pantethine as inhibitory agent of hepatic fibrosis | DAIICHI SEIYAKU CO (JP) | 1994-04-13 | — | — | EP | disclosed |
| US-4937266-A | ADMINISTERING PANTETHINE | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0323855-A2 | Pantethine as inhibitory agent of hepatic fibrosis | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092775-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | PTGS1 484/4885KCNH2 2012/4885 |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | PTGS1 484/4885KCNH2 2012/4885 |
| US-20050101565-A1 | Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders | PCSK9, PCSK7, HMGCR | PTGS1 1883/4885KCNH2 1240/4885 |
| US-20060003947-A1 | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols | TTPA, PLA2G10, GSTO1 | PTGS1 105/4885KCNH2 3938/4885 |
| US-20070292501-A1 | CHEWABLE SOFT GELATIN CAPSULES | GMPS, PIGS, GYS1 | PTGS1 76/4885KCNH2 3908/4885 |
| US-20210277000-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | PTGS1 484/4885KCNH2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.